Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer.
miRNA
quantitative PCR
tumor marker
urothelial carcinoma
voided urine cytology
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 May 2020
27 May 2020
Historique:
received:
05
05
2020
revised:
20
05
2020
accepted:
26
05
2020
entrez:
31
5
2020
pubmed:
31
5
2020
medline:
17
2
2021
Statut:
epublish
Résumé
Currently, voided urine cytology (VUC) serves as the gold standard for the detection of bladder cancer (BCa) in urine. Despite its high specificity, VUC has shortcomings in terms of sensitivity. Therefore, alternative biomarkers are being searched, which might overcome these disadvantages as a useful adjunct to VUC. The aim of this study was to evaluate the diagnostic potential of the urinary levels of selected microRNAs (miRs), which might represent such alternative biomarkers due to their BCa-specific expression. Expression levels of nine BCa-associated microRNAs (miR-21, -96, -125b, -126, -145, -183, -205, -210, -221) were assessed by quantitative PCR in urine sediments from 104 patients with primary BCa and 46 control subjects. Receiver operating characteristic (ROC) curve analyses revealed a diagnostic potential for miR-96, -125b, -126, -145, -183, and -221 with area under the curve (AUC) values between 0.605 and 0.772. The combination of the four best candidates resulted in sensitivity, specificity, positive and negative predictive values (NPV), and accuracy of 73.1%, 95.7%, 97.4%, 61.1%, and 80.0%, respectively. Combined with VUC, sensitivity and NPV could be increased by nearly 8%, each surpassing the performance of VUC alone. The present findings suggested a diagnostic potential of miR-125b, -145, -183, and -221 in combination with VUC for non-invasive detection of BCa in urine.
Identifiants
pubmed: 32471285
pii: ijms21113814
doi: 10.3390/ijms21113814
pmc: PMC7312501
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Med Sci (Basel). 2020 Mar 13;8(1):
pubmed: 32183076
World J Urol. 2009 Jun;27(3):295-300
pubmed: 19271220
Nucleic Acids Res. 2015 Sep 3;43(15):7173-88
pubmed: 26170234
Int J Oncol. 2012 Nov;41(5):1871-8
pubmed: 22961325
Oncotarget. 2018 Apr 17;9(29):20658-20669
pubmed: 29755679
Onco Targets Ther. 2015 Aug 11;8:2089-96
pubmed: 26316777
Oncotarget. 2016 Dec 27;7(52):86290-86299
pubmed: 27863434
Neoplasma. 2016;63(5):799-808
pubmed: 27468885
Cancer Cytopathol. 2020 May;128(5):341-347
pubmed: 31977131
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Int J Clin Exp Pathol. 2017 Aug 01;10(8):8303-8313
pubmed: 31966681
J Cancer Res Clin Oncol. 2016 Aug;142(8):1673-95
pubmed: 26660324
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Oncotarget. 2017 Apr 11;8(15):24668-24678
pubmed: 28160564
Clin Chem. 2011 Jul;57(7):954-68
pubmed: 21632885
Mod Pathol. 2015 May;28(5):612-30
pubmed: 25412849
J Urol. 2014 Jan;191(1):261-9
pubmed: 23831312
Oncotarget. 2017 Apr 18;8(16):27547-27568
pubmed: 28187437
Mol Biol Rep. 2014 Dec;41(12):8127-35
pubmed: 25189652
Eur Urol Oncol. 2018 Sep;1(4):307-313
pubmed: 31100252
Urol Oncol. 2010 Nov-Dec;28(6):655-61
pubmed: 19375957
PLoS One. 2014 Jul 11;9(7):e100793
pubmed: 25014919
Eur Urol. 2014 Aug;66(2):253-62
pubmed: 24472711
Clin Genitourin Cancer. 2016 Oct;14(5):e493-e499
pubmed: 27157639
Tumour Biol. 2015 Dec;36(12):9545-52
pubmed: 26138586
Cancers (Basel). 2015 Dec 18;7(4):2466-85
pubmed: 26694467
J Urol. 2017 Mar;197(3 Pt 1):590-595
pubmed: 27746284
Am J Transl Res. 2015 Nov 15;7(11):2500-9
pubmed: 26807194
Onco Targets Ther. 2017 May 22;10:2665-2673
pubmed: 28579804
Bladder Cancer. 2018 Oct 29;4(4):353-363
pubmed: 30417046
Genes (Basel). 2017 Nov 22;8(11):
pubmed: 29165379
Ann Intern Med. 2015 Dec 15;163(12):922-31
pubmed: 26501851
Br J Cancer. 2016 Feb 16;114(4):454-62
pubmed: 26812572
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Eur J Cancer. 2016 Feb;54:131-138
pubmed: 26761785
Clin Genitourin Cancer. 2012 Jun;10(2):106-13
pubmed: 22386240
Eur Urol. 2019 May;75(5):853-860
pubmed: 30553612
Int J Clin Exp Med. 2015 Sep 15;8(9):15432-40
pubmed: 26629032
Oncotarget. 2016 Jan 19;7(3):3255-66
pubmed: 26657502
J Urol. 2012 Aug;188(2):615-23
pubmed: 22704449
Oncotarget. 2016 Jul 5;7(27):42805-42825
pubmed: 27081087
PLoS One. 2014 Feb 10;9(2):e84311
pubmed: 24520312
Science. 1945 May 18;101(2629):519-20
pubmed: 17775845
Gene. 2013 Sep 15;527(1):26-32
pubmed: 23791657
Oncotarget. 2017 May 9;8(19):32370-32379
pubmed: 28423688
Bladder Cancer. 2016 Jul 27;2(3):301-317
pubmed: 27500198
Cancer Res. 2009 Nov 1;69(21):8472-81
pubmed: 19843843
Cancer Prev Res (Phila). 2015 Mar;8(3):208-21
pubmed: 25586904
Can Urol Assoc J. 2013 Jan-Feb;7(1-2):28-32
pubmed: 22630336
Investig Clin Urol. 2016 Jun;57 Suppl 1:S60-76
pubmed: 27326409
Medicine (Baltimore). 2015 Sep;94(37):e1272
pubmed: 26376375
Cancer Sci. 2011 Mar;102(3):522-9
pubmed: 21166959
Int J Cancer. 2013 Dec 1;133(11):2631-41
pubmed: 23686449
Oncotarget. 2016 Jun 21;7(25):38731-38740
pubmed: 27231851
BJU Int. 2017 Mar;119(3):371-380
pubmed: 28058776
World J Urol. 2019 Sep;37(9):1741-1749
pubmed: 30283995
Diagnostics (Basel). 2020 Jan 13;10(1):
pubmed: 31941070
PLoS One. 2011 Mar 28;6(3):e18286
pubmed: 21464941
Carcinogenesis. 2012 Jun;33(6):1126-33
pubmed: 22491715
Med Oncol. 2015 Jan;32(1):413
pubmed: 25511320
Cancer Res. 2009 Jun 1;69(11):4851-60
pubmed: 19487295
Int Braz J Urol. 2013 Jan-Feb;39(1):95-101; discussion 102
pubmed: 23489501
Transl Res. 2015 Jun;165(6):731-9
pubmed: 25620614
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Int J Cancer. 2016 May 15;138(10):2334-45
pubmed: 26489968
World J Urol. 2019 Nov 1;:
pubmed: 31676912